Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It is sadly what it is.
The world operates on anything but a level playing field.
I’m not anti Tory (it just happens they’re calling the shots at the moment), but you only have to see the blatant cronyism around PPE and the gift of mega contracts, with people scratching each other’s backs in plain sight.
SNG is having to take the long route with other options a done deal pre paid and the regulation a formality.
I remain convinced the science they have pursued is bang on and it will come good with plenty of market left.
This is the potential dependable multi tool bit of kit which may be the go to save lives and money in the future.
Yes - this doesn’t worry me either. Big pharma get more attention because, like it or not, they have the power to get themselves notices. RM even hinted at / discussed around the point himself last week.
It is just frustrating from my point of view that we have, what I believe, to be an excellent treatment and yet getting pre-orders is so difficult. However, all understandable and I shared the article for interest.
What we can see from this though, is the governments are still spending on treatments that aren’t due to deliver for some time even in light of the recent vaccine news. This is really good news because it means when (if) we get positive news from P3 we will be likely to be able to secure orders.
As frustrating as elements of the article are, overall I think this is a positive story for marketing prospects.
I see they have an ADE (antibody dependant Enhancement ) prevention fraction in Mabs treatment . This also a problem in with vaccines .I do not know if its a potential prob with our treatment? Joey ?
Thanks.
The guidance is Q4 and the aim is November, so I expect a P3 RNS within the next two weeks.
My wild guess is Monday 30th November.
All I can think that we need to start p3 trial ASAP. Did the company give any guide on the latest webinar please all. I feel timing is critical now. Gla
Government has spent small change on pre-orders compared to overall economic and health costs on vaccines. We know that we weren't included in the Recovery trial because of supply and the capital raised in April and October were to complete critical trials and develop supply chain.
First bit complete with brilliant P2 results. Contracts in place for P3 and ramp up of supply chain. Next bit is complete P3. Then we'll have government orders, whether it's ours or another one.
AZ could be a competitor but we're a bit ahead of them and will have orders in place whilst they are still trialling. And depending on how the WHO recommendation develops Gilead might want to jump in with a huge offer for an approved therapeutic, particularly for their home market
Do not forget we are a broad spectrum antiviral Mabs struggle against mutations according to Fauci
This a worry. For some reason we just can’t get any pre orders for the treatment.
The Gov has bought 4 or 5 vaccines, what's to stop a similar announcement by UK Gov or other Governments re SNG....`to buy of 100k treatments of sng001 subject to successful phase 3`. Presumably not all eggs in one basket, and 4-or 5 vaccines on order.
Meant to read ‘big pharma’!
A real shame that big pharma always hold the punch with governments.
https://apple.news/A2ifApOA1TaqZ8bRmlVDi8A
“ The U.K. has agreed to buy a million doses of AstraZeneca Plc’s Covid-19 antibody treatment if it succeeds in Phase 3 trials....”